NIKKEI 225
28,804.85 +96.25 (+0.34%) HANG SENG
26,126.93 +109.43 (+0.42%) CRUDE OIL
83.82 +0.06 (+0.07%) GOLD FUTURES
1,793.30 -3.00 (-0.17%) DOW
35,677.02 +73.92 (+0.21%) BTC-GBP
44,270.14 -479.74 (-1.07%)
Hutchison China MediTech Limited (HCM)
After hours: 04:41PM EDT
| Previous close | 32.17 |
| Open | 32.42 |
| Bid | 30.02 x 1100 |
| Ask | 37.45 x 1000 |
| Day's range | 32.01 - 32.44 |
| 52-week range | 23.67 - 43.94 |
| Volume | 96,859 |
| Avg. volume | 198,428 |
| Market cap | 5.609B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.24 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 46.57 |
- Zacks
Hutchison China MediTech (HCM) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Hutchison China MediTech (HCM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Globe Newswire
HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 28, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) announces that new and updated clinical data from several ongoing combination studies of surufatinib (SULANDA® in China) or fruquintinib (ELUNATE® in China) with PD-1 inhibitors were presented at the 24th Chinese Society of Clinical Oncology (CSCO) Annual Meeting which has been taking place on September 25-29, 2021. SURUFATINIB Title:A phase I
- Globe Newswire
HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture
HONG KONG and FLORHAM PARK, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, further to its announcement in March 2021 and following receipt of regulatory approval, it has completed the sale of its entire indirect interest in Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), a non-core and non-consolidated over-the-counter (“OTC”) drug joint venture business, to GL Mountrose Investment
